References
- Lanier A, Kelly J, Maxwell J, McEvoy T, Homan C. Cancer in Alaska Native People, 1969–2003. AK Med. 2006; 48: 30–59.
- Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007; 56: 1–24.
- National Cancer Institute at the National Institutes of Health. Cervical cancer; Available from: http://www.cancer.gov/cancertopics/types/cervical; Accessed on May 27, 2011.
- Walboomers J, Jacobs M, Manos M, Bosch FX, Kummer JA, Shah KV, etal. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 1–3.
- Bosch F, de Sanjose S. Human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; 31: 3–13.
- Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366: 991–8.
- Munoz N, Bosch F, Sanjose S, de Herrero R, Castellsague X, Shah K, etal. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med. 2003; 348: 518–27.
- Dunne E, Unger E, Sternberg M, McQuillan G, Swan D, Patel S, Markowitz L. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813–9.
- Sebbelov A, Davidson M, Kjaer S, Jensen H, Gregoire L, Hawkins I, etal. Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska Natives, Greenland Natives and Danish Caucasians. Microbes Infect. 2000; 2: 121–6.
- Alaska Native Tumor Registry. 2011; Anchorage, Alaska: Alaska Native Epidemiology Center, Alaska Native Tribal Health Consortium.
- Steinau M, Patel S, Unger E. Efficient DNA extraction for HPV genotyping in formalin-fixed paraffin-embedded tissues. J Mol Diag. 2011; 13: 377–81.
- Brown D, Kjaer S, Iversen O, Hernandez-Avila M, Wheeler C, Perez G, etal. The impact of quadrivalent human Papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16–26 years. J Infect Dis. 2009; 199
- Wheeler C, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Perez G, etal. The impact of quadrivalent human papillomavirus (HPV types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine types in generally HPV-naïve women aged 16–26 years. J Infect Dis. 2009; 199